Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Operating Expenses (2016 - 2025)

OptimizeRx's Operating Expenses history spans 16 years, with the latest figure at $15.5 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 29.73% year-over-year to $15.5 million; the TTM value through Sep 2025 reached $64.8 million, down 22.39%, while the annual FY2024 figure was $73.1 million, 5.46% up from the prior year.
  • Operating Expenses for Q3 2025 was $15.5 million at OptimizeRx, roughly flat from $15.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $28.7 million in Q4 2023 and bottomed at $6.8 million in Q1 2021.
  • The 5-year median for Operating Expenses is $13.4 million (2023), against an average of $14.5 million.
  • The largest annual shift saw Operating Expenses soared 115.82% in 2023 before it crashed 36.03% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $11.8 million in 2021, then grew by 13.15% to $13.3 million in 2022, then soared by 115.82% to $28.7 million in 2023, then plummeted by 36.03% to $18.4 million in 2024, then dropped by 15.9% to $15.5 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Operating Expenses are $15.5 million (Q3 2025), $15.4 million (Q2 2025), and $15.5 million (Q1 2025).